Renal cell carcinoma, also known by the eponym Grawitz tumor, is the most common form of kidney cancer arising from the renal tubule. It is the most common type of kidney cancer in adults. Initial therapy is with surgery. It is notoriously resistant to radiation therapy and chemotherapy, although some cases respond to immunotherapy.
Experimental drug shows promise in advanced kidney cancer
Kidney Cancer :: Experimental drug shows promise in advanced kidney cancer
A new drug has shown promise in patients with advanced kidney cancer whose options run out after their tumour fails to respond to the cutting edge therapy.In the study, scientists gave axitinib to 62 patients whose kidney cancer had spread and who had not benefited from a standard treatment, sorafenib, a targeted therapy designed to disrupt cell division signals in cancer cells and block the tumour’s ability to form new blood vessels that help it grow. Fourteen of the patients also had been given – to no avail – another similarly targeted drug, sunitinib, after the sorafenib had failed to work. Axitinib works similarly to the other two but is believed to be more potent.
“More than half the patients – 51 percent – experienced tumour shrinkage and in 23 percent of them the shrinkage is considered significant,” said lead investigator Dr Brian I. Rini, an associate professor of medicine at the Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio, USA, and a paid member of the Pfizer scientific advisory board. “Preliminary analysis shows the progression-free survival was on average more than 7.7 months. We think these results are impressive because these patients were heavily pre-treated and with drugs thought to be similar to axitinib.
“The disease progressed in only 24 percent of patients, which we think is low in this kind of setting,” Rini added. The study found the tumour remained stable in 37 percent of the patients.
“Historically, metastatic kidney cancer has been very tough to treat, with a median survival of 12 months. Through the results of this trial, it appears that axitinib is a very active drug in renal cell cancer that can benefit a large number of patients,” Rini added.
The drug’s maker, Pfizer, paid for the study. Axitinib is also being tested in advanced pancreatic, thyroid, lung and breast cancers.
(Kidney Cancer :: Experimental drug shows promise in advanced kidney cancer published at SpiritIndia on Wednesday, September 26, 2007)
Kidney Cancer
Search more information on Kidney Cancer, Kidney Cancer booksRecently posted related articles on Kidney Cancer :
- Kidney Cancer :: Experimental drug shows promise in advanced kidney cancer
- Kidney Cancer :: Reactivating a critical gene lost in kidney cancer reduces tumor growth
- Kidney Cancer :: B.C. first to fund new drug therapies for kidney cancer
- Kidney Cancer :: 2 drugs work better together than either alone against kidney cancer
- Kidney Cancer :: FDA approves new drug for advanced kidney cancer
- Kidney Cancer :: Translocation kidney cancer after chemotherapy in childhood
- Kidney Cancer :: Mouse FH knockout resembles human renal cell cancer
- Kidney Cancer :: New vaccine aims to slow down progression of kidney cancer
- Kidney Cancer :: Sutent achieves first line EAU approval for kidney cancer
- Kidney Cancer :: A new pharmaceutical drug that halts progress of metastatic kidney cancer
Most related articles:
- Kidney Cancer :: Experimental drug shows promise in advanced kidney cancer- Kidney Cancer :: Bayer and Onyx announce pivotal Nexavar kidney cancer study - 15.8
- Kidney Cancer :: Avastin shows positive outcomes in patients with advanced kidney cancer - 14.1
- Kidney Cancer :: Pfizer's Sutent approved for use in Kidney Cancer in Europe - 12
- Kidney Cancer :: New vaccine aims to slow down progression of kidney cancer - 12
- Kidney Cancer :: A new pharmaceutical drug that halts progress of metastatic kidney cancer - 11.8
- Kidney Cancer :: FDA approves new drug for advanced kidney cancer - 11.7
- Kidney Cancer :: B.C. first to fund new drug therapies for kidney cancer - 10.5
- Breast Cancer :: Experimental drug delays breast cancer - 10.1
- Kidney :: Fish oil may help kidney disease sufferers - 10
»» Healthcare :: $22 million gift from Alfred Taubman launches new biomedical research institute
«« PTSD :: Post-traumatic stress symptoms in adolescent children of cancer patients
The information provided on SpiritIndia.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Spirit India comply with the HONcode principles for trustworthy health information.
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com
Health, Business, Science, Sports, Entertainment, Technology
©2002-2009 SpiritIndia.com